Stock OCPH OCTOBER PHARMA S.A.E
Add to a list
To use this feature you must be a member
Log inSign up

Financials October Pharma S.A.E

Equities

OCPH

EGS380R1C018

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
100 EGP 0.00% Intraday chart for October Pharma S.A.E 0.00% 0.00%
Mar. 10 October Pharma S.A.E Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 October Pharma S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 382.2 396 600 978.1 1,200 1,200
Enterprise Value (EV) 1 677.4 636.2 846.1 1,036 1,516 1,479
P/E ratio 24.8 x 11.7 x 6.8 x 8.17 x 10.6 x 7.98 x
Yield - - 3% - - -
Capitalization / Revenue 0.95 x 0.76 x 1.1 x 1.49 x 1.65 x 1.19 x
EV / Revenue 1.69 x 1.22 x 1.56 x 1.58 x 2.08 x 1.46 x
EV / EBITDA 9.51 x 5.53 x 5.16 x 4.79 x 6.85 x 4.49 x
EV / FCF -3.61 x 10.8 x -113 x 5.17 x -6.34 x 59.3 x
FCF Yield -27.7% 9.23% -0.89% 19.3% -15.8% 1.69%
Price to Book 2.46 x 2.19 x 2.36 x 2.88 x 2.82 x 2.04 x
Nbr of stocks (in thousands) 12,000 12,000 12,000 12,000 12,000 12,000
Reference price 2 31.85 33.00 50.00 81.51 100.0 100.0
Announcement Date 3/4/19 2/23/20 3/14/21 2/28/22 3/10/24 3/10/24
1EGP in Million2EGP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 400.7 523.1 543.4 655 727.4 1,012
EBITDA 1 71.22 115 163.9 216.3 221.2 329.2
EBIT 1 61.66 98.42 145 195.5 199.2 307.1
Operating Margin 15.39% 18.81% 26.69% 29.85% 27.39% 30.35%
Earnings before Tax (EBT) 1 28.99 46.97 113.2 164.6 173.5 244.7
Net income 1 18.32 33.83 88.26 119.8 130.7 182.1
Net margin 4.57% 6.47% 16.24% 18.29% 17.98% 18%
EPS 2 1.284 2.819 7.355 9.983 9.477 12.53
Free Cash Flow 1 -187.7 58.7 -7.52 200.3 -239 24.95
FCF margin -46.83% 11.22% -1.38% 30.58% -32.86% 2.47%
FCF Conversion (EBITDA) - 51.02% - 92.6% - 7.58%
FCF Conversion (Net income) - 173.52% - 167.23% - 13.7%
Dividend per Share - - 1.500 - - -
Announcement Date 3/4/19 2/23/20 3/14/21 2/28/22 3/10/24 3/10/24
1EGP in Million2EGP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 295 240 246 57.4 316 279
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 4.145 x 2.088 x 1.502 x 0.2654 x 1.428 x 0.8466 x
Free Cash Flow 1 -188 58.7 -7.52 200 -239 24.9
ROE (net income / shareholders' equity) 11.9% 20.1% 40.6% 40.4% 34.2% 35.9%
ROA (Net income/ Total Assets) 8.53% 11.3% 15.8% 21.1% 16.6% 18.4%
Assets 1 214.7 298.2 557.2 568.1 789.2 990.9
Book Value Per Share 2 13.00 15.00 21.20 28.30 35.50 49.10
Cash Flow per Share 2 0.7400 1.430 0.1800 1.390 0.5800 3.770
Capex 1 33.2 33.2 5.65 19.7 92.7 35.3
Capex / Sales 8.3% 6.35% 1.04% 3.01% 12.74% 3.49%
Announcement Date 3/4/19 2/23/20 3/14/21 2/28/22 3/10/24 3/10/24
1EGP in Million2EGP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
OCTOBER PHARMA S.A.E Stock October Pharma S.A.E
0.00% 25.05M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. OCPH Stock
  4. Financials October Pharma S.A.E